Time to say goodbye: from Barcelona to Milan and the modern management of hepatocellular carcinoma  

作　　者：Georgia Sofia Karachaliou Nikolaos Dimitrokallis Dimitrios Moris 

机构地区：[1]Division of Gastroenterology,Department of Medicine,Duke University Medical Center,Durham,NC,USA [2]st Department of Surgery&Organ Transplant Unit,Evangelismos General Hospital,Athens,Greece [3]Department of Surgery,Duke University Medical Center,Durham,NC,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第3期548-550,共3页肝胆外科与营养（英文）

摘　　要：Hepatocellular carcinoma(HCC)is the most common primary liver malignancy and one of the most common causes of cancer-related death with the projection to increase during the next few decades(1).During the last 3 decades,several staging systems have been introduced for the stratification of the prognosis and management of HCC of all stages.There is no consensus regarding the universal implementation of one staging system since all the proposed classifications have limitations(2).The Barcelona Clinic Liver Cancer(BCLC)Staging System remains the most widely classification system used for HCC management guidelines that incorporates tumor size,presence of metastatic disease,portal hypertension,Child-Turcotte-Pugh score,total bilirubin and performance status.However,it does not account for tumoral behavior,and it is very“conservative”(restrictive)regarding resectability,especially for BCLC-B patients who might benefit from surgical management(3,4).Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy,as well as the possibility for downstaging patients to undergo surgery or transplant with curative intent.

关 键 词：Hepatocellular carcinoma(HCC) Barcelona Clinic Liver Cancer(BCLC) tumor burden score 

分 类 号：R735.7[医药卫生—肿瘤]